Prestige Biologics Past Earnings Performance
Past criteria checks 0/6
Prestige Biologics has been growing earnings at an average annual rate of 14.3%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been declining at an average rate of 43.3% per year.
Key information
14.3%
Earnings growth rate
30.9%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -43.3% |
| Return on equity | -39.5% |
| Net Margin | -2,259.2% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Prestige Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 1,746 | -39,442 | 7,639 | 31,848 |
| 31 Mar 23 | 69 | -47,594 | 5,962 | 32,473 |
| 31 Dec 22 | 16 | -49,718 | 5,202 | 30,970 |
| 30 Sep 22 | 2,834 | -62,586 | 4,514 | 32,752 |
| 30 Jun 22 | 3,077 | -46,036 | 3,745 | 32,129 |
| 31 Mar 22 | 3,227 | -49,189 | 3,661 | 32,003 |
| 31 Dec 21 | 3,227 | -39,378 | 3,770 | 25,097 |
| 30 Sep 21 | 407 | -43,046 | 3,965 | 23,261 |
| 30 Jun 21 | 150 | -43,685 | 4,072 | 22,214 |
| 31 Mar 21 | 0 | -25,266 | 1,843 | 16,470 |
| 31 Dec 20 | 0 | -31,033 | 3,722 | 18,364 |
| 30 Sep 20 | 0 | -15,370 | 3,458 | 12,477 |
| 30 Jun 20 | 0 | -14,644 | 3,185 | 10,321 |
| 31 Mar 20 | 185 | -25,913 | 5,328 | 11,218 |
| 31 Dec 19 | 185 | -22,057 | 3,141 | 8,751 |
| 31 Dec 18 | 0 | 10 | 2,650 | 74 |
| 31 Dec 17 | 0 | -1,782 | 920 | 172 |
Quality Earnings: A334970 is currently unprofitable.
Growing Profit Margin: A334970 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A334970's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare A334970's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A334970 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).
Return on Equity
High ROE: A334970 has a negative Return on Equity (-39.52%), as it is currently unprofitable.